News & Updates
Filter by Specialty:

Tislelizumab a new Tx alternative for very high-risk bladder cancer?
06 Mar 2025
byAudrey Abella
In the phase II pilot TRUCE-02 trial, tislelizumab plus low-dose nab-paclitaxel shows promising clinical antitumour activity and is well tolerated in patients with extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC).
Tislelizumab a new Tx alternative for very high-risk bladder cancer?
06 Mar 2025
EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer
05 Mar 2025
byAudrey Abella
The updated analysis of the phase III EV-302 trial continues to show the benefit of front-line enfortumab vedotin plus pembrolizumab (EV+P) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).